Current Treatment Options in Neurology

, Volume 3, Issue 4, pp 333–346

Anxiety disorders in neurologic illness

  • Robert D. Davies
  • Sherri L. Gabbert
  • Paula D. Riggs

Opinion statement

  • Anxiety disorders frequently occur in individuals with neurologic illness. Anxiety may be a symptom of or a reaction to the neurologic disorder, a medication side effect, or a comorbid condition. The most common anxiety disorders seen in neurologic patients are panic disorder, generalized anxiety disorder, social phobia, and obsessive-compulsive disorder (OCD). Very often, these conditions go unrecognized (and therefore untreated) or are attributed to being a normal response to having a neurologic illness. However, if they are not treated, anxiety disorders can significantly increase morbidity and mortality in neurologic patients.

  • Selective serotonin reuptake inhibitors (SSRIs) should be considered the first-line of pharmacologic treatment, because they offer a broad spectrum of efficacy in the anxiety disorders, are generally well tolerated, and are effective in treating comorbid depression. Benzodiazepines, although most effective for acute anxiety, are now considered adjunctive or second-line treatments.

  • Cognitive behavioral therapy and other behavioral treatments are effective in the treatment of anxiety disorders. They should be considered primary treatments for patients who cannot tolerate or prefer not to take medications.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994, 51:8–19.PubMedGoogle Scholar
  2. 2.
    Stein MB, Heuser IJ, Juncos JL, et al.: Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry 1990, 147:217–220.PubMedGoogle Scholar
  3. 3.
    Richard JH, Schiffer RB, Kurtan R: Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1996, 8:383–392.PubMedGoogle Scholar
  4. 4.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Press; 1994.Google Scholar
  5. 5.
    Barlow DH, Gorman JM, Shear MK, et al.: Cognitivebehavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000, 283:2529–2536.PubMedCrossRefGoogle Scholar
  6. 6.
    Wise MG, Rundell JR: Anxiety and neurological disorders. Semin Clin Neuropsychiatry 1999, 4:98–102. Excellent review of diagnostic issues and treatment options for anxiety occurring in neurological conditions.PubMedGoogle Scholar
  7. 7.
    Ketter TA, Post RM, Theodore WH: Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999, 53(suppl):S53–67.PubMedGoogle Scholar
  8. 8.
    Hollander E, Cohen LJ: The assessment and treatment of refractory anxiety. J Clin Psychiatry 1994, 55(suppl):27–31.PubMedGoogle Scholar
  9. 9.
    Davies RD, Dubovsky SL, Gabbert S, et al.: Treatment resistance in anxiety disorders. Bull Menninger Clin 2000, 64(suppl A):A22-A36.PubMedGoogle Scholar
  10. 10.
    Roy-Byrne PP, Cowley DS: Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1994-1995, 1:151–160.Google Scholar
  11. 11.
    Cowley DS, Ha EH, Roy-Byrne PP: Determinants of pharmacologic treatment failure in panic disorder. Br J Psychiatry 1997, 58:555–561.Google Scholar
  12. 12.
    Riether AM: Anxiety in patients with multiple sclerosis. Semin Clin Neuropsychiatry 1999, 4:103–113. Detailed discussion of the complex interplay between multiple sclerosis, the treatment of multiple sclerosis, and comborbid anxiety.PubMedGoogle Scholar
  13. 13.
    Rosenstein DL, Nelson JC, Jacobs SC: Seizures associated with antidepressants: a review. J Clin Psychiatry 1993, 54:289–299.PubMedGoogle Scholar
  14. 14.
    Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism [letter to the editor]. Am J Psychiatry 1991, 148:274.PubMedGoogle Scholar
  15. 15.
    Breslau N, Kilbey M, Andreski P: Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991, 48:1069–1074.PubMedGoogle Scholar
  16. 16.
    Bruce M, Scott N, Shine P, et al.: Anxiogenic effects of caffeine in patients with anxiety disorders. Arch Gen Psychiatry 1992, 49:867–869.PubMedGoogle Scholar
  17. 17.
    Bourin M, Baker GB, Badwejn J: Neurobiology of panic disorder. J Psychosom Res 1998, 44:163–180.PubMedCrossRefGoogle Scholar
  18. 18.
    Roberts MD, Emsley RA, Pienaar WP, et al.: Anxiety disorders among abstinent alcohol-dependent patients. Psychiatr Serv 1999, 50:1359–1361.PubMedGoogle Scholar
  19. 19.
    Marshall JR: Alcohol and substance abuse in panic disorder. J Clin Psychiatry 1997, 58(suppl 2):46–49.PubMedGoogle Scholar
  20. 20.
    Lepine JP, Pelissolo A: Social phobia and alcoholism: a complex relationship. J Affect Disord 1998, 50(suppl 1):S23-S28.PubMedCrossRefGoogle Scholar
  21. 21.
    Mackenzie A, Funderburk FR, Allen RP: Sleep, anxiety, and depression in abstinent and drinking alcoholics. Subst Use Misuse 1999, 34:347–361.PubMedGoogle Scholar
  22. 22.
    Johnson JG, Cohen P, Pine DS, et al.: Association between cigarette smoking and anxiety during adolescence and early adulthood. JAMA 2000, 284:2348–2351.PubMedCrossRefGoogle Scholar
  23. 23.
    Kushner MG, Abrams K, Borchardt C: The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 2000, 20:149–171.PubMedCrossRefGoogle Scholar
  24. 24.
    Dick CL, Bland RC, Newman SC: Panic disorder. Acta Psychiatr Scand Suppl 1994, 45–53.Google Scholar
  25. 25.
    Turgeon L, Marchand A, Dupuis G: Clinical features in panic disorder with agoraphobia: a comparison of men and women. J Anxiety Disord 1998, 12:539–553.PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson SK, Frederick J, Kaufman M, et al.: A controlled investigation of bodywork in multiple sclerosis. J Altern Complement Med 1999, 5:237–243.PubMedGoogle Scholar
  27. 27.
    Husted C, Pham L, Hekking A, et al.: Improving quality of life for people with chronic conditions: the example of t’ai chi and multiple sclerosis. Altern Ther Health Med 1999, 5:70–74.PubMedGoogle Scholar
  28. 28.
    Solari A, Filippini G, Gasco P, et al.: Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999, 52:57–62.PubMedGoogle Scholar
  29. 29.
    Goddard AW, Charney DS: SSRIs in the treatment of panic disorder. Depress Anxiety 1998, 8(suppl 1):114–120.PubMedCrossRefGoogle Scholar
  30. 30.
    Nutt DJ: Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry 1998, 59(suppl 8):24–28.PubMedGoogle Scholar
  31. 31.
    Papp LA, Sinha SS, Martinez JM, et al.: Low-dose venlafaxine treatment of panic disorder. Psychopharmacol Bull 1998, 34:207–209.PubMedGoogle Scholar
  32. 32.
    Carpenter LL, Leon Z, Yasmin S, et al.: Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999, 11:81–86.PubMedCrossRefGoogle Scholar
  33. 33.
    DeMartinis NA, Schweizer E, Rickels K: An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996, 57:245–258.PubMedGoogle Scholar
  34. 34.
    Ballenger JC, Burrows GD, DuPont RL, et al.: Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: Efficacy in shortterm treatment. Arch Gen Psychiatry 1988, 45:413–422.PubMedGoogle Scholar
  35. 35.
    Harvey KV, Balon R: Augmentation with buspirone: a review. Ann Clin Psychiatry 1995, 7:143–147.PubMedGoogle Scholar
  36. 36.
    Torta R, Keller R: Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999, 40(suppl 10):S2-S20. Excellent summary of the association between seizure activity and psychiatric symptoms. Particularly good discussion of the possible etiologies behind this relationship.PubMedCrossRefGoogle Scholar
  37. 37.
    Lee DO, Helmers SL, Steingard RJ, et al.: Case study: seizure disorder presenting as panic disorder with agoraphobia. J Am Acad Child Adolesc Psychiatry 1997, 36:1295–1298.PubMedCrossRefGoogle Scholar
  38. 38.
    Breslau N: Psychiatric comorbidity in migraine. Cephalalgia 1998, 18(suppl 22):56–61.PubMedGoogle Scholar
  39. 39.
    Marazziti D, Toni C, Pedri S, et al.: Headache, panic disorder and depression: comorbidity or a spectrum? Neuropsychobiology 1995, 31:125–129.PubMedCrossRefGoogle Scholar
  40. 40.
    Merikangas KR, Stevens DE: Comorbidity of migraine and psychiatric disorders. Neurol Clin 1997, 15:115–123.PubMedCrossRefGoogle Scholar
  41. 41.
    Keck PE, Merikangas KR, McElroy SL, et al.: Diagnostic and treatment implications of psychiatric comorbidity with migraine. Ann Clin Psychiatry 1994, 6:165–171.PubMedGoogle Scholar
  42. 42.
    Baetz M, Bowen RC: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998, 43:73–77.PubMedGoogle Scholar
  43. 43.
    Ontiveros A, Fontaine R: Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992, 17:78–80.PubMedGoogle Scholar
  44. 44.
    Laakmann, G, Schule C, Lorkowski G, et al.: Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharm 1998, 136:357–366.CrossRefGoogle Scholar
  45. 45.
    Davidson JR, DuPont RL, Hedges D, et al.: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999, 60:528–535.PubMedCrossRefGoogle Scholar
  46. 46.
    Goodnick PJ, Puig A, DeVane CL, et al.: Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999, 60:446–448.PubMedCrossRefGoogle Scholar
  47. 47.
    Ludwig CL, Weinberger DR, Bruno G, et al.: Buspirone, Parkinson’s disease, and the locus ceruleus. Clin Neuropharmacol 1986, 9:373–378.PubMedCrossRefGoogle Scholar
  48. 48.
    Bonifati V, Fabrizio E, Cipriani R, et al.: Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994, 17:73–82.PubMedCrossRefGoogle Scholar
  49. 49.
    Magee WJ, Eaton WW, Wittchen HU, et al.: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 1996, 53:159–168.PubMedGoogle Scholar
  50. 50.
    Davidson JR, Potts NS, Richichi E, et al.: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharm 1993, 13:423–428.CrossRefGoogle Scholar
  51. 51.
    Turner SM, Beidel DC, Wolff PL, et al.: Clinical features affecting treatment outcome in social phobia. Behav Res Ther 1996, 34:795–804.PubMedCrossRefGoogle Scholar
  52. 52.
    Baldwin D, Bobes J, Stein D, et al.: Paroxetine in social phobia/social anxiety disorder. Br J Psychiatry 1999, 175:120–126.PubMedGoogle Scholar
  53. 53.
    Black B, Uhde TW, Tancer ME: Fluoxetine for the treatment of social phobia. J Clin Psychopharm 1992, 12:293–295.CrossRefGoogle Scholar
  54. 54.
    Katzelnick DJ, Kobak KA, Greist JH, et al.: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995, 152:1368–1371.PubMedGoogle Scholar
  55. 55.
    Stein MB, Fyer AJ, Davidson JR, et al.: Fluvoxamine in the treatment of social phobia: a double-blind, placebo-controlled study. Am J Psychiatry 1999, 156:756–760.PubMedGoogle Scholar
  56. 56.
    Liebowitz MR, Schneier P, Campeas R, et al.: Phenelzine vs atenolol in social phobia: a placebo controlled trial. Arch Gen Psychiatry 1992, 49:290–300.PubMedGoogle Scholar
  57. 57.
    Tesei S, Antonini A, Canesi M, et al.: Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 2000, 15:986–989.PubMedCrossRefGoogle Scholar
  58. 58.
    Rasmussen SA, Eisen JL: The epidemiology and differential diagnosis of obsessive-compulsive disorder. J Clin Psychiatry 1992, 53(suppl):4–10.PubMedGoogle Scholar
  59. 59.
    Pauls DL, Towbin KE, Leckman JF, et al.: Gilles de la Tourette’s syndrome and obsessive-compulsive disorder. Arch Gen Psychiatry 1986, 43:1180–1182.PubMedGoogle Scholar
  60. 60.
    Sheppard DM, Bradshaw JL, Purcell R, et al.: Tourette’s and comorbid syndromes: obsessive compulsive and attention deficit hyperactivity disorder. A common etiology? Clin Psychol Rev 1999, 19:531–52.Google Scholar
  61. 61.
    Greist JH, Chouinard G, Duboff E, et al.: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995, 52:289–295.PubMedGoogle Scholar
  62. 62.
    Tollefson GD, Rampey AH, Potvin JH, et al.: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994, 51:559–567.PubMedGoogle Scholar
  63. 63.
    Zohar J, Judge R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996, 69:468–474.CrossRefGoogle Scholar
  64. 64.
    Jacobsen FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995, 56:423–429.PubMedGoogle Scholar
  65. 65.
    McDougle CJ, Goodman WK, Leckman JF, et al.: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994, 51:302–306.PubMedGoogle Scholar
  66. 66.
    Weiss EL, Potenza MN, McDougle CJ, et al.: Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an openlabel case series. J Clin Psychiatry 1999, 60:524–527.PubMedCrossRefGoogle Scholar
  67. 67.
    McDougle CJ, Epperson CN, Pelton GH, et al.: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000, 57:794–801.PubMedCrossRefGoogle Scholar
  68. 68.
    Rasmussen S, Greenberg B, Mindus P, et al.: Neurosurgical approaches to intractable obsessivecompulsive disorder. CNS Spectrums 2000, 5:23–34. Concise review of the history of surgical interventions for OCD, as well as the current status of this treatment.PubMedGoogle Scholar
  69. 69.
    Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharm 1999, 19:341–348.CrossRefGoogle Scholar
  70. 70.
    Craske MG, Barlow DH: Panic disorder and agoraphobia. In In Clinical Handbook of Psychological Disorders, Second Edition. Edited by Barlow DH. New York: The Guilford Press, 1993:1–47.Google Scholar
  71. 71.
    Juster HR, Heimberg RG: Social phobia: longitudinal course and long-term outcome of cognitivebehavioral treatment. Psychiatr Clin North Am 1995, 18:821–842.PubMedGoogle Scholar
  72. 72.
    Foa EB, Steketee GS, Milby JB: Behavior therapy with obsessive-compulsives: from theory to treatment. In Obsessive-compulsive disorders: psychological and pharmacological treatment. Edited by Mavissakalian M. New York: Plenum Press; 1985.Google Scholar
  73. 73.
    Ettinger AB, Weisbrot DM, Nolan EE, et al.: Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia 1998, 39:595–599.PubMedCrossRefGoogle Scholar
  74. 74.
    Riggs PD, Baker S, Mikulich SK, et al.: Depression in substance-dependent delinquents. J Am Acad Child Adolesc Psychiatry 1995, 34:764–771.PubMedCrossRefGoogle Scholar
  75. 75.
    Manassis K, Monga S: A therapeutic approach to children and adolescents with anxiety disorders and associated comorbid conditions. J Am Acad Child Adolesc Psychiatry 2001, 40:115–117.PubMedCrossRefGoogle Scholar
  76. 76.
    Bernstein G, Borchardt CM, Perwien AR: Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996, 35:110–1119.CrossRefGoogle Scholar
  77. 77.
    Bernstein GA, Shaw K: Practice parameters for the assessment and treatment of anxiety disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1993, 32:1089–1098.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Robert D. Davies
    • 1
  • Sherri L. Gabbert
    • 1
  • Paula D. Riggs
    • 1
  1. 1.Department of PsychiatryUniversity of Colorado Health Sciences CenterDenverUSA

Personalised recommendations